Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study

• Published in: The Korean journal of internal medicine Vol. 39; no. 5; pp. 793 - 800
• Main Authors: Kim, Yongcheol, Roh, Ji Woong, Lee, Oh-Hyun, Heo, Seok-Jae, Im, Eui, Cho, Deok-Kyu, Kim, Byeong-Keuk
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Association of Internal Medicine 01.09.2024; The Korean Association of Internal Medicine; 대한내과학회
• Subjects: Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Anticholesteremic Agents - administration & dosage; Anticholesteremic Agents - adverse effects; Biomarkers - blood; Cholesterol, LDL - blood; dyslipidemia; Dyslipidemias - blood; Dyslipidemias - diagnosis; Dyslipidemias - drug therapy; Female; Humans; lipids; Male; Middle Aged; myocardial infarction; Myocardial Infarction - blood; Myocardial Infarction - diagnosis; Myocardial Infarction - drug therapy; Original; PCSK9 Inhibitors; Percutaneous Coronary Intervention; Proprotein Convertase 9; Retrospective Studies; Time Factors; Treatment Outcome; 내과학; Myocardial infarction; Lipids; Dyslipidemia
• ISSN: 1226-3303; 2005-6648; 2005-6648
• DOI: 10.3904/kjim.2024.080

Background/Aims: Achieving rapid reduction of low-density lipoprotein cholesterol (LDL-C) levels below 55 mg/dL in patients with acute myocardial infarction (AMI) can be challenging with statins alone. This single-center, retrospective study aimed to assess the impact of single-dose injection of evolocumab 140 mg on LDL-C levels during the peri-percutaneous coronary intervention (PCI) period in patients with AMI.Methods: A total of 95 patients with AMI who underwent PCI were divided into the evolocumab (n = 50) and non-evolocumab (n = 45) groups.Results: The percentage change of LDL-C level at 1–3 weeks from baseline was 78.4 ± 13.4% reduction in the evolocumab group versus 45.6 ± 22.6% in the non-evolocumab group, with a mean difference of -33.5% between the groups (95% CI: -42.6 to -24.5%; p < 0.001). The achievement rate of LDL-C levels below 55 mg/dL at 1–3 weeks was significantly higher in the evolocumab group than in the non-evolocumab group (97.7% vs. 60.0%, p < 0.001).Conclusions: Patients with AMI who received single-dose injection of evolocumab 140 mg during the peri-PCI period had a significantly greater LDL-C reduction and higher proportion of patients achieved the target LDL-C level in the early phase AMI than those who did not receive evolocumab.